Short bowel syndrome (SBS) is the leading cause of chronic intestinal failure in adults and most commonly follows extensive small-bowel resection. The resulting loss of absorptive surface and regulatory feedback leads to a spectrum of malabsorption syndromes, ranging from compensated intestinal insufficiency to intestinal failure requiring long-term parenteral support. Clinical outcomes are determined more by postoperative anatomy than by residual length alone, particularly the presence of colon continuity and the preservation of the distal ileum and the ileocecal region. The pathophysiology of SBS integrates reduced absorptive capacity, accelerated transit, gastric hypersecretion, disordered bile acid handling, microbiome perturbation, and impaired enteroendocrine signalling. Intestinal adaptation, driven by luminal nutrients and trophic hormones such as GLP-2, can partially restore function over months to years, enabling stepwise reduction of parenteral support in selected patients. Modern care is centred on structured intestinal rehabilitation delivered by multidisciplinary teams, combining individualised fluid-electrolyte strategy, optimised oral/enteral nutrition, targeted pharmacotherapy to control secretion and motility, prevention and management of catheter-related complications, and selective reconstructive surgery. Disease-modifying therapy with GLP-2 analogues can reduce parenteral support requirements in SBS-associated intestinal failure, while transplantation remains reserved for refractory, life-threatening complications. This review summarises current concepts and evidence-based principles for diagnosis, phenotype stratification, rehabilitation, and long-term surveillance in adult SBS.
Epidermolysis bullosa (EB) is a hereditary multisystemic disease caused by genetic defects in the skin's structural proteins. Depending on the type of disease, symptoms vary from localised fragility and bullae to a widespread generalised form, including extracutaneous manifestations. In the most severe forms, EB causes death in the earliest period of life. The treatment of EB is complex and usually requires the involvement of several different specialists. Without curative therapy, treatment is oriented towards supportive care, symptom control, and preventing mild to severe complications. Vector gene therapy Vyjuvek (beremagene geperpavec), based on the herpes simplex virus type 1, is a new hope for treating wounds in patients older than six months who suffer from dystrophic forms of EB.